Related Experiment Video

Updated: May 19, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Multidrug resistance-associated protein 1 predicts relapse in Iranian childhood acute lymphoblastic leukemia

Frouzandeh Mahjoubi1, Soodeh Akbari

  • 1Clinical Genetic Department, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. frouz@nrcgeb.ac.ir

Asian Pacific Journal of Cancer Prevention : APJCP
|August 21, 2012
PubMed

Insights

Multidrug resistance (MDR) in pediatric leukemia is often linked to the multidrug resistance-associated protein 1 (MRP1) gene. This study found MRP1 gene overexpression in most Iranian pediatric leukemia patients during relapse.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Multidrug resistance (MDR) significantly hinders chemotherapy efficacy in malignant disorders.
  • The multidrug resistance-associated protein 1 (MRP1) is a key gene implicated in MDR.
  • Systematic investigation of MRP1's role in Iranian pediatric leukemia patients is lacking.

Purpose of the Study:

  • To investigate the association between the MRP1 gene and MDR phenotype in Iranian pediatric leukemia patients.
  • To analyze MRP1 mRNA levels using real-time RT-PCR technology.

Main Methods:

  • Real-time RT-PCR technology was employed.
  • MRP1 gene expression levels were quantified in pediatric leukemia patients.
  • Data were analyzed for associations with clinical characteristics.

Main Results:

  • Overexpression of the MRP1 gene was observed in the majority of Iranian pediatric leukemia patients at the time of relapse.
  • No significant correlation was found between MRP1 mRNA levels and clinical factors such as cytogenetic subgroups or FAB subtypes.

Conclusions:

  • MRP1 gene overexpression is a common finding in relapsed pediatric leukemia in the Iranian population.
  • While MRP1 is associated with MDR in this cohort, its expression levels do not correlate with specific clinical or cytogenetic subtypes.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...